KKR to acquire Integer Holdings for $127 per share in all-cash deal

InstantWhy

The deal

Investing.com reports that KKR has agreed to acquire Integer Holdings for $127 per share in cash. The transaction would take the medical device contract manufacturer private. Neither KKR nor Integer Holdings has independently confirmed the deal, and no further details on the total transaction value or timing have been disclosed.

Why it matters

Medical device manufacturing offers recurring revenue from long-term supplier relationships, exactly the cash flow profile buyout firms prize in a high-rate environment. The per-share price represents a concrete valuation, though without Integer's recent trading price or market capitalization the premium paid is not yet clear.

Deal context

KKR has been active in energy and infrastructure deals this year, including a transaction in August in which it acquired a stake in TotalEnergies' renewables business as part of a portfolio reshuffle by the French energy major. The firm is among the largest private equity players in healthcare, where it has pursued both provider and supplier assets. Integer Holdings manufactures critical components used in implantable medical devices, a market characterized by high regulatory barriers and long customer relationships that make switching suppliers costly.

What has to happen next

The companies will need to disclose deal terms in regulatory filings if the transaction proceeds, including the total equity value, any debt assumption, and the expected closing timeline. Integer shareholders would receive the cash consideration upon deal completion, subject to regulatory approvals and customary closing conditions.

InstantWhy

Skyworks Solutions clears antitrust waiting period for Qorvo merger

The chipmaker can now proceed with the deal after the Hart-Scott-Rodino review period ended without objection

SWKS QRVO 2026-08-03 11:41

InstantWhy

U.S. stocks rise as Iran deal talk eases geopolitical risk premium

Equity markets climbed after the White House signaled progress on Iran negotiations, shrugging off weakness in

2026-08-03 11:07

InstantWhy

Barclays upgrades Clariant after court ruling reduces litigation risk

The Swiss specialty chemicals maker saw its analyst rating lifted following a legal decision that eases uncert

CLNX Clariant 2026-08-03 11:04